SNOA - Sonoma Pharmaceuticals, Inc.
IEX Last Trade
2.76
0.040 1.449%
Share volume: 200
Last Updated: Thu 26 Dec 2024 08:19:20 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.30%
PREVIOUS CLOSE
CHG
CHG%
$2.72
0.04
1.47%
Fundamental analysis
19%
Profitability
25%
Dept financing
10%
Liquidity
75%
Performance
3%
Performance
5 Days
1.87%
1 Month
-6.51%
3 Months
-14.95%
6 Months
1,416.67%
1 Year
1,261.60%
2 Year
169.05%
Key data
Stock price
$2.76
DAY RANGE
$2.69 - $2.72
52 WEEK RANGE
$0.14 - $5.93
52 WEEK CHANGE
$1,280.18
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Amy M. Trombly
Region: US
Website: sonomapharma.com
Employees: 180
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: sonomapharma.com
Employees: 180
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for various applications. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, a prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses. It also offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites.
Recent news